UK markets open in 2 hours 58 minutes

Allergy Therapeutics plc (AGY.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
5.30-0.30 (-5.36%)
At close: 04:35PM BST

Allergy Therapeutics plc

Dominion Way
Worthing BN14 8SA
United Kingdom
44 1903 844 700

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees612

Key executives

NameTitlePayExercisedYear born
Mr. Manuel LlobetCEO & Executive Director411.98kN/A1965
Mr. Shaun Antony FurlongCFO & Executive DirectorN/AN/A1976
Ms. Beverly LeesGroup Operations DirectorN/AN/AN/A
Dr. Murray SkinnerChief Scientific OfficerN/AN/AN/A
Mr. Santiago PuigBusiness Development DirectorN/AN/AN/A
Ms. Sue BakerHead of Human ResourcesN/AN/AN/A
Simon PiggottHead of Clinical ScienceN/AN/AN/A
Alan BullimoreHead of Communication & Market DevelopmentN/AN/AN/A
Mr. Russell PicketGroup Financial ControllerN/AN/AN/A
Karley Charlotte Mouatt CheesmanCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Corporate governance

Allergy Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.